Deep Braining...
TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

Evotec SE American Depositary Shares (EVO)
Evotec SE American Depositary Shares
XNAS:EVO
3.08
-4.64%

Ask
$3.17 - 1.00
Bid
$3.09 - 1.00
Low
$3.1
High
$3.21
Open
$3.21
Prev Close
$3.23
52W High
5.1
52W Low
2.84
Volume
50280
Avg Vol (3m)
92336.4
Float
336849606.75
Chart
TendieTensor AI Analysis

Company
Asset Type: American Depository Receipt Common
SIC Code:
Sector: Health Technology
Industry: Pharmaceuticals: Major
Date Listed: 06/02/1999
Primary Exchange: XNAS

Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.

TendieTensor AI Analyst Recommendation:
Fundamentals
Total Employees:
4,766
P/E (TTM)
-6.280000
P/B (TTM)
1.178790
Round Lot
100
Composit FIGI
BBG000LFTJ81
Share Class FIGI
BBG001T2N0N0
Share Class Shares Outstanding
355.11M
Weighted Shares Outstanding
355.20M

Technicals
RSI (14)
MACD Line
MACD Signal
SMA 20
SMA 50
EMA 50
Trend
Short Interest
Days to Cover
Higher = harder to cover
Short Interest Δ
Prev: —
Short Volume Ratio (Today)
5D avg:
Squeeze Score (0–100)
Discussion
Login to participate in discussions.
Recent News
Related Stocks

Based on the portfolios of people who own EVO. This is a list generated by trading data from 3rd party trading platforms, and it's not a recommendation.